Officials said Thursday that San Francisco-based McKesson Corp. would occupy a new 340,000-square-foot distribution center in Clear Lake, ending a nearly yearlong mystery about the company's identity.
TepoFlex® polyethylene (PE) biocontainer assemblies provide secure, robust fluid handling options. TepoFlex® polyethylene-based biocontainers are available in standard assembly designs from 50 mL to 1,000 L, utilizing the exact same materials of construction throughout the entire portfolio. This streamlines scale- up efforts so that...
Celgene Corporation has announced that the FDA has expanded the existing indication for REVLIMID® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM).
A dozen unimmunized students in Port Angeles, Washington have been asked to stay home, after a classmate was exposed to measles.
"GMA" contributor Becky Worley went undercover to see how clean free makeup testers really are.
Under the terms of the agreement, NewLink Genetics will receive a payment of $20 million in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
Florida has eclipsed California to become the state with the highest number of consumers buying health coverage through new insurance markets under the Affordable Care Act, according to federal statistics released Wednesday.
Contaminated medical instruments are to blame for infecting seven patients — including two who died — with an antibiotic-resistant and potentially deadly "superbug" at Ronald Reagan UCLA Medical Center, hospital officials said. A total of 179 patients may be infected.
Hundreds of products are being pulled from store shelves after traces of peanut were found in cumin spice — a life-threatening danger to some people with peanut allergies.
Kite Pharma has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport.
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf in Advanced MelanomaFebruary 19, 2015 8:18 am | News | Comments
Genentech, a member of the Roche Group, announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s New Drug Application (NDA) for cobimetinib in combination with Zelboraf ® (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma
In July of this year it will be six years since my father dies from pancreatic cancer. As I write this in late February it’s been four weeks since my father-in-law passed away from mesothelioma, a cancer caused by exposure to asbestos.
Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET), including two phase III ready orthobiologic product candidates designed to improve bone repair.
The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 15.1%, according to research and consulting firm GlobalData.